Interactions between herbal medicines and conventional drugs have recently been reported; the most significant herb with such drug interactions is Saint John's wort, an inducer of cytochrome P450 3A3/4, an enzyme responsible for clearance of many clinically important drugs from the body. Foods (especially grapefruit) and habits or lifestyle factors such as smoking or alcohol consumption may also alter the metabolism of drugs through effects on the cytochrome P450 system. The authors review here the functioning of the drug-metabolizing enzymes and discuss their particular significance in cancer chemotherapy treatment. They then present the herbal medicines, foods, and lifestyle factors that induce or inhibit drug-metabolizing enzymes that are important for both cancer chemotherapy drugs and drugs used adjunctively in cancer treatment. It is notable that no actual herb-drug interactions have been reported clinically in cancer treatment, and their potential for interaction still must be regarded as theoretical. Although some chemotherapy patients may be interested in taking herbal medicines that could potentially interact with cancer chemotherapy agents, it may be wise to counsel them to use other means of addressing the problems for which they use specific herbs during the time they receive chemotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1177/153473540200100118DOI Listing

Publication Analysis

Top Keywords

cancer chemotherapy
16
herbal medicines
12
herb-drug interactions
8
cytochrome p450
8
lifestyle factors
8
drug-metabolizing enzymes
8
cancer treatment
8
cancer
6
chemotherapy
6
drugs
5

Similar Publications

Background: Real-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.

Methods: A chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423).

View Article and Find Full Text PDF

Introduction: Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP-ribose) polymerase inhibitors. We analyzed real-world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring germline BRCA mutations in Italy, where olaparib is not reimbursed for this indication.

Methods: Clinico/pathological data of pancreatic cancer patients with documented BRCA1-2 germline pathogenic variants who had received first-line chemotherapy for metastatic disease were collected from 23 Italian oncology departments and the impact of olaparib exposure on overall survival (OS) was analyzed.

View Article and Find Full Text PDF

: (PG) has been widely researched as a conductant drug for the treatment of lung diseases by ancient and modern traditional Chinese medicine (TCM) practitioners. Inspired by the mechanism and our previous finding about fructans and fructooligosaccharides from (FFPG), we developed a nano drug delivery system (NDDS) targeting lung cancer. The aim was to improve the efficiency of the liposomal delivery of Paclitaxel (PTX) and enhance the anti-tumor efficacy.

View Article and Find Full Text PDF

Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges.

Pharmaceutics

January 2025

Research Centre for Life Science and Healthcare, Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute (CBI), University of Nottingham Ningbo China, Ningbo 315000, China.

Malignant growth is expected to surpass other significant causes of death as one of the top reasons for dismalness and mortality worldwide. According to a World Health Organization (WHO) study, this illness causes approximately between 9 and 10 million instances of deaths annually. Chemotherapy, radiation, and surgery are the three main methods of treating cancer.

View Article and Find Full Text PDF

Advances in Pure Drug Self-Assembled Nanosystems: A Novel Strategy for Combined Cancer Therapy.

Pharmaceutics

January 2025

Nanjing Medical Center for Clinical Pharmacy, Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.

Nanoparticle-based drug delivery systems hold great promise for improving the effectiveness of anti-tumor therapies. However, their clinical translation remains hindered by several significant challenges, including intricate preparation processes, limited drug loading capacity, and concerns regarding potential toxicity. In this context, pure drug-assembled nanosystems (PDANSs) have emerged as a promising alternative, attracting extensive research interest due to their simple preparation methods, high drug loading efficiency, and suitability for large-scale industrial production.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!